This study reveals a mechanism by which NFYAv2 promotes anti-tumor effects through the transcriptional regulation of PCK1 and induction of gluconeogenesis, indicating its importance as a therapeutic target for HCC. The gene discussed is PCK1; the disease is hepatocellular carcinoma.